Illumina's new stock repurchase program effective in returning value to shareholders

Illumina, Inc. (NASDAQ:ILMN) today announced that its Board of Directors has approved a new stock repurchase program, authorizing the Company to repurchase in the aggregate up to $75 million of its outstanding common stock. The Company has terminated the $120 million repurchase program announced on October 24, 2008 after repurchasing an aggregate of $70.7 million of its outstanding common stock in 2008.

"Given the continued strength of our cash flow, we believe that this program is an effective mechanism to return value to our shareholders," said Jay Flatley, Illumina's President and Chief Executive Officer.

Under the program authorized by its Board of Directors, any shares repurchased will be done so under a 10b5-1 trading program. The purchases will be funded from existing cash balances.

A trading program under Rule 10b5-1 allows a company to purchase its shares at times when it otherwise might be prevented from doing so under insider trading laws or self-imposed trading blackout periods. A broker selected by Illumina will have the authority under the terms and limitations specified in the plan to repurchase shares on the Company's behalf in accordance with the terms of the plan.

The 10b5-1 share repurchase period will commence on August 25, 2009. The aggregate amount of shares purchased pursuant to the plan will not exceed $75 million (excluding commissions, taxes and other charges and expenses). There is no guarantee as to the exact number of shares that will be repurchased under the stock repurchase program and the Company may terminate the plan at any time.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Illumina, Inc.. (2019, June 19). Illumina's new stock repurchase program effective in returning value to shareholders. News-Medical. Retrieved on December 30, 2024 from https://www.news-medical.net/news/20090825/Illuminas-new-stock-repurchase-program-effective-in-returning-value-to-shareholders.aspx.

  • MLA

    Illumina, Inc.. "Illumina's new stock repurchase program effective in returning value to shareholders". News-Medical. 30 December 2024. <https://www.news-medical.net/news/20090825/Illuminas-new-stock-repurchase-program-effective-in-returning-value-to-shareholders.aspx>.

  • Chicago

    Illumina, Inc.. "Illumina's new stock repurchase program effective in returning value to shareholders". News-Medical. https://www.news-medical.net/news/20090825/Illuminas-new-stock-repurchase-program-effective-in-returning-value-to-shareholders.aspx. (accessed December 30, 2024).

  • Harvard

    Illumina, Inc.. 2019. Illumina's new stock repurchase program effective in returning value to shareholders. News-Medical, viewed 30 December 2024, https://www.news-medical.net/news/20090825/Illuminas-new-stock-repurchase-program-effective-in-returning-value-to-shareholders.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
H3Africa Initiative selects Illumina to develop new array for genome-wide association studies